Accelerating Revenue GrowthTTM revenue growth of +78% indicates expanding demand and successful product uptake across diabetes, diagnostics and hospital segments. Sustained top-line expansion increases the installed base for consumables and services, drives recurring revenue potential and provides scale for margin and margin-investment improvements over the medium term.

Healthy Gross & EBIT MarginsA gross margin near 46% and positive EBIT margin (~7%) reflect structural pricing power and a favorable product mix in higher-value healthcare segments. These margins create operating leverage that can absorb SG&A and R&D, supporting durable cash generation and resilience to cyclical pressures over the next several months.

Strong Cash GenerationRobust operating cash flow (~¥41.5B) and free cash flow (~¥32.0B), with recent FCF growth, provide internal funding for capex, servicing debt, dividends and strategic investments. Reliable cash conversion reduces reliance on external financing and gives the company flexibility to deleverage or invest in product and geographic expansion over the medium term.

Bears Say

Thin & Volatile Net ProfitsA net margin of about 1.6% coupled with historical swings and losses in FY2022–FY2024 indicates fragile bottom-line conversion. Profit volatility weakens earnings quality and makes cash returns to shareholders and reinvestment plans less predictable, increasing risk if revenue growth slows or costs rise.

Elevated LeverageDebt at roughly 1.7x equity, while improved, remains elevated and constrains financial flexibility. Higher leverage increases interest expense sensitivity and reduces room for strategic moves; in the event of margin compression or slower top-line momentum, the company could face tighter capital allocation and slower deleveraging.

Modest Return On EquityTTM ROE of about 4% signals limited effectiveness in converting revenue and cash into shareholder returns. Persistently low ROE suggests capital intensity or operational inefficiencies that could hinder long-term shareholder value creation unless profitability or asset efficiency meaningfully improves.

PHC Holdings Corp. News

2GY Upcoming Earnings Report: What to Expect?

PHC Holdings Corp. (2GY) is scheduled to report 2nd quarter earnings on 11/12/2025. Regarding Q2 estimates, Wall Street...

3M ago

2GY FAQ

What was PHC Holdings Corp.’s price range in the past 12 months?

PHC Holdings Corp. lowest stock price was €4.96 and its highest was €6.90 in the past 12 months.

What is PHC Holdings Corp.’s market cap?

PHC Holdings Corp.’s market cap is €712.46M.

When is PHC Holdings Corp.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were PHC Holdings Corp.’s earnings last quarter?

Currently, no data Available

Is PHC Holdings Corp. overvalued?

According to Wall Street analysts PHC Holdings Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PHC Holdings Corp. pay dividends?

PHC Holdings Corp. does not currently pay dividends.

What is PHC Holdings Corp.’s EPS estimate?

PHC Holdings Corp.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PHC Holdings Corp. have?

PHC Holdings Corp. has 126,721,820 shares outstanding.

What happened to PHC Holdings Corp.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of PHC Holdings Corp.?

Currently, no hedge funds are holding shares in DE:2GY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PHC Holdings Corp.

PHC Holdings Corporation, through its subsidiaries, develops, manufactures, and sells medical devices, healthcare technology solutions, and life science products. The company offers blood glucose monitoring systems and other testing/analysis devices, as well as data linkage solutions; anatomical pathology solutions, such as instruments, microscope slides, and dyeing reagents; and equipment and services for various sample preservation and cell culture in the life sciences field. It also provides healthcare IT products in the field of medical information systems for clinics and healthcare insurance pharmacies. In addition, the company engages in clinical testing, diagnostic reagents, and drug development support businesses. The company was formerly known as Panasonic Healthcare Holdings Co., Ltd. and changed its name to PHC Holdings Corporation in April 2018. The company was founded in 2014 and is headquartered in Tokyo, Japan.